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Dural sinus thrombosis is a rare disease and can carry
a high rate of morbidity and mortality. There are
several treatments, but no definitive results have been
obtained. Systemic anticoagulant therapy has
produced poor clinical responses and some side effects,
so more effective recanalization of affected vessels
may be required. Due to the recent advances in
angiographic techniques, pharmacologic preparations,
and catheter technology, direct selective venography
and thrombolytic therapy with non-fibrin specific
agents are now possible.
We successfully treated a case of acute superior
sagittal sinus and right transverse sinus thrombosis in
a 39-year-old male with streptokinase via highly
selective venography. Recanalization of the dural
venous sinus was visualized after treatment.
CASE PRESENTATION
A 39-year-old male who had smoked for several years
had a 20-day history of headache. Initially, the headache
was dull and occurred several times a day for several
minutes each. The headache resolved spontaneously
without any sequelae. However, it became a constant
throbbing pain over the bilateral temporal and frontal
area 5 days before presentation, and he had drowsy
consciousness, initial focal seizure, and convulsion of
the right upper limb with secondary generalization
twice on March 3, 2001. He was sent to hospital on the
same day because of the aggravated headache, drowsy
consciousness, and seizure.
At the first hospital, secondary generalized seizure
became more frequent in spite of treatment with
phenytoin, and consciousness gave way to stupor with
progressive deterioration in his clinical condition; thus,
he was transferred to our Emergency Department on
March 3, 2001.
Once at the Emergency Department, his seizure
was immediately treated with continuous phenytoin
300 mg at a therapeutic level of about 16 µg/mL, and
he underwent emergency whole-brain magnetic
resonance imaging (MRI). There was no significant
ventricle dilation, but high signal intensity in the high
vertex in parietal and frontal views were apparent on
T2-weighted images (Figure 1). Low signal intensity
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on the T1-weighted image, with cortical venous
congestion and edema, was also noted (Figure 2).
Magnetic resonance venography (MRV) also revealed
obstructions in the transverse and superior sagittal
sinuses (Figure 3).
Cerebral angiography was performed via the right
femoral artery for suspected venous sinus thrombosis.
Initially, diagnostic right common carotid artery
injection was performed. There was evidence of
Figure 1. T2-weighted image shows high signal intensity in the
left parietal and right frontal cortex.
Figure 2. T1-weighted non-enhanced image shows low signal
intensity in the left parietal and right frontal cortex.
increased intracranial pressure with relatively delayed
enhancement of the right cerebral hemisphere
parenchyma. The superior sagittal sinus was not fully
opacified and there was anterior venous drainage into
the anterior ophthalmic area, consistent with
thrombosis of the clinical superior sagittal sinus and
right transverse sinus. The same results were found on
left common carotid artery study, together with
patency of the left transverse sinus and delayed phase
of the right internal jugular vein (Figure 4).
The patient and family gave informed consent for
emergency direct intravenous thrombolytic therapy
via the right femoral vein. The catheter was fed through
the right femoral vein to the superior vena cava and
Figure 3. Magnetic resonance venography shows an obstruction
in: (A) the right transverse sinus; and (B) the superior sagittal
sinus.
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Figure 4. Left common carotid artery with delayed phase of right
internal jugular vein.
Figure 5. (A) Venography shows thrombus formation in the
superior sagittal and right transverse sinuses. (B) Thrombosis
formation is visible in the superior sagittal sinus.
DISCUSSION
The signs and symptoms of sinus thrombosis are
numerous and non-specific, and the time course during
which they develop may be variable. They include
headache, stroke, hydrocephalus, papilledema, visual
loss, and often coma and death. Headache is found in
approximately 75% of cases and is thought to result
B
A
then into the right internal jugular vein. With the aid
of a microcatheter, the right transverse sinus, sigmoid
sinus, and the posterior part of the superior sagittal
sinus area were reached. The stasis of flow noted
during angiographic study was consistent with clinical
sagittal sinus thrombosis, and thrombosis formation
was also visible (Figure 5).
Streptokinase (3 million U) was targeted to the
occipital area of the sagittal sinus through the
microcatheter, and partial relief of thrombotic vessels
was noted. After injection of a further 1.5 million U of
streptokinase, the superior sagittal and right transverse
venous sinuses became patent. The patient was sent to
the neurologic intensive care unit for further
evaluation. Anti-epileptic drugs and heparin were
prescribed for seizure and prevention of thrombus
formation. No more seizures were noted and
consciousness became much clearer after direct
thrombolytic treatment. Follow-up MRV revealed
patency of the venous sinus (Figure 6), and alert
consciousness was noted on the following day.
U n f o r t u n a t e l y ,  o n  t h e  t h i r d  d a y  a f t e r
thrombolytic treatment, fever and leukocytosis
(white blood cell count, 14,300/µL) were noted.
Positive culture results were not obtained from
blood, urine, or sputum culture samples, nor was
there any evidence of infection. However, after empiric
antibiotic therapy (ampicillin with sulbactam and
gentamicin), the fever declined gradually and
biochemical laboratory data returned to normal several
days later. No more seizures were noted under the
control of the anti-epileptic drug, phenytoin, at a
therapeutic level of about 18 µg/mL.
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from elevated intracranial pressure [1]. Clinical
manifestations are variable, ranging from headache to
seizure, and hemorrhage infarction to coma [2];
symptoms may not be severe if the thrombosis is
incomplete or if there is collateral circulation.
Cerebral CT is usually the initial radiographic study
used to evaluate severe spontaneous headache, seizure,
or intracranial  lesions.  The characteristic CT
appearance of sinus thrombosis is biparietal, and less
often bifrontal, because most cortical vein thromboses
originate from clots in the sagittal sinus [3]. Isolated
cerebral venous thrombosis is far less frequent and
causes partial seizure and headache [3], as in our
patient. Although the scans may be initially read as
normal in cases of sinus thrombosis, several signs
have been considered of diagnostic value for cerebral
venous thrombosis, such as the empty delta or empty
triangle sign, indicating a non-enhancing clot inside
the sinus whole walls, enhanced on contrast injection
[4,5].
Cerebral angiography has been considered the
definitive study to diagnose sinus thrombosis, seen as
lack of filling of the sinus [5,6]. Recently, MRI, magnetic
resonance angiography (MRA), and MRV have become
the diagnostic studies of choice in evaluating sinus
thrombosis [6]. MRI, MRA, and MRV detect both the
presence of clots and the absence of normal flow
within the sinus. In addition, they are almost non-
invasive compared to traditional angiography, so have
been used widely in fol low-up studies after
thrombolytic treatment or in initial diagnosis.
Mechanical thrombolysis via microballoon
angioplasty [7] or with a microsnare [8], direct
thrombolysis with thrombolytic agents, and systemic
anticoagulant agents are now used widely to treat
sinus thromboses [9–12]; however, no definitive
treatment guidelines have been established. Systemic
heparin or warfarin treatment used to be considered
effective treatment [13], but the systemic side effects
and the frequent monitoring required have limited
their clinical use. Although subcutaneous low-
molecular-weight heparin has been used in clinical
trials [14], its role in the treatment of stroke is still
unclear. Recently, direct thrombolytic agents have
been advocated in sinus thrombotic patients with
intracranial hemorrhage [15].
Several kinds of fibrin-specific and non-fibrin-
specific thrombolytic agents are available for clinical
treatment (Table 1). However, no single agent is
preferred, despite tissue plasminogen activator being
more commonly used recently [5].
Thrombolytic therapy has played a critical part in
cardiovascular medicine, particularly as a result of the
Figure 6. Follow-up magnetic resonance venography shows
patency of the superior sagittal sinus.
Table 1. Characteristics of currently available thrombolytic agents
Streptokinase Anistreplase Urokinase Alteplase Reteplase
Molecular weight (daltons) 47,000 131,000 31,000–55,000 70,000 39,571
Plasma clearance time (min) 15–25 50–90 15–20 4–8 11–19
Fibrin specificity Minimal Minimal Moderate Moderate Moderate
Plasminogen binding Indirect Indirect Direct Direct Direct
Potential allergic reaction Yes Yes No No No
Typical dose 1.5 million U 30 U 2 million U 100 mg (max) 10 U + 10 U
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recognition that infarction is caused by a blood clot
[4]. In arterial thrombosis, localized vascular occlusion
is initiated by changes at the endothelial surface,
possibly involving a blood plaque or ulceration. The
activation, adherence, and aggregation of platelets,
along with the release of coagulation factors, initiate
the clotting cascade, resulting in the formation of the
various components of a thrombus. This allows the
development of a critical concentration of thrombin,
sufficient to convert fibrinogen to fibrin. After cross-
linkage, fibrin forms a clot anchored to the original
site of endothelial surface derangement, and makes
the clot much stronger as it stretches.
Despite the various possible pathogeneses
described, there is currently no definite mechanism
for venous sinus thrombosis. Predisposing factors and
conditions associated with sinus thrombosis include
puerperium, congenital and acquired cardiac disease,
blood dyscrasia, infection, medications (especially
synthetic steroids), coagulation factor abnormalities,
autoimmune inflammatory disease, connective tissue
disorders, dehydration, and trauma [16,17]. The
pathogenesis is likely to be complicated, as the
components of the thrombus are not those in the
normal physiologic thrombosis cascade, so non-fibrin-
specific agents may provide more suitable treatment
than fibrin-specific agents.
Non-fibrin-specific agents seem to be more
acceptable than fibrin-specific drugs in venous
thrombosis, because the subacute progressive course
of sinus venous thrombosis permits the use of non-
fibrin-specific agents with longer plasma clearance
times than the fibrin-specific agents. The subacute
evolution of venous sinus thrombosis also offers much
more time to perform direct thrombolytic treatment
than arterial thrombosis.
Non-fibrin-specific agents include streptokinase
and urokinase. Urokinase seems to be used more
commonly than streptokinase because it has caused
fewer anaphylactic reactions during recent research
[7,10,15,18,19] (Table 2). The anti-streptokinase titer
rapidly rises to 50 to 100 times the pre-infusion level,
remaining there for many months or even years from a
few days after treatment [12,20,21]. This also makes
repeated administration impractical (except very early
after initial dosing) if other thrombolytic treatment is
required.
Leukocytosis without any positive pathogenic
culture was noted in this patient after thrombolytic
treatment with streptokinase. This phenomenon may
have resulted from the above considerations, and
clinicians using this treatment should be aware of this
problem.
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